Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targetsMay Han, Lawrence Steinman, Sun‐Il Hwang et al.|Nature|2008Cited by 519
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trialLudwig Kappos, Paul D. Crowe, Giancarlo Comi et al.|Nature Medicine|2000Cited by 515
1,25-Dihydroxyvitamin D <sub>3</sub> Ameliorates Th17 Autoimmunity via Transcriptional Modulation of Interleukin-17ASneha Joshi, Sawsan Youssef, Luiz-Carlos Pantalena et al.|Molecular and Cellular Biology|2011Cited by 456
Type II monocytes modulate T cell–mediated central nervous system autoimmune diseaseMartin S. Weber, Scott S. Zamvil, Thomas Prod’homme et al.|Nature Medicine|2007Cited by 448
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trialGıancarlo Comı, Jeffrey A. Cohen, Ludwig Kappos et al.|The Lancet Neurology|2019Cited by 286